A MODIFIED GLUTAMIC ACID DECARBOXYLASE (GAD)

Abstract: A modified GAD especially characterized by a substantially preserved immunogenicity in connection with diabetes compared with a non-modified GAD and a reduced or non-existent effectivity in connection with a GABA-synthesis. The invention relates also to a method for manufacturing a modified GAD, a method for supplying a modified GAD, nucleotide sequence encoding the modified GAD, a vector containing the nucleic acid sequence, a host, a pharmaceutical composition comprising modified GAD and use thereof for treating and/or preventing autoimmune disorders such as IDDM.

Description: A modi ied glutamic acid decarboxylase (GAD) The present invention relates to a genetically-modified recombinant form of the 65 kDa human glutamic acid decarboxylase (hGAD65) that retains structural integrity for immuno-reacti vity characteristic of the unmodified form, but that is without (or with considerably reduced) enzyme activity. The novel modified GAD is advantageously used in pharmaceutical compositions for treating autoimmune diseases. Backpjound of the invention The inhibitory neurotransmitter γ-aminobutyric acid (GABA), derived from L-glutamic acid by GAD is present in brain as well as several tissues outside the central nervous system. Biological functions of GAD and GABA extend beyond regulation of neurotransmission to include effects on the immune system as well as modulation of cell proliferation, protein synthesis and metabolism. GAD has recently been associated with autoimmune insulin-dependent diabetes mellitus (IDDM) (Boekkeskov et al, Nature 347: 151 (1990), incoφorated by reference) because ofthe increased incidence of LDDM in patients with stiff-man syndrome, a disease associated with autoanti bodies against GAD. Antibodies from diabetic sera have also been shown to bind GAD. At least two different GAD, i.e. GAD 65 and 67 have been identified and sequenced in human beings. hGAD65 and hGAD67 have several epitopes in common. However, different epitopes are involved in different reactions and contexts. Binding ofthe coenzyme pyridoxal-5'-phospate (PLP) to GAD was first reported by Roberts & Frankel in 1951 (J. Biol. Chem. 188:789, fully incorporated in the description by reference), and formation of a Schiff base during GAD-mediated decarboxylation was subsequently proposed by W T Jenkins 1961, Fed. Proc. 20:978 (fully incorporated in the description by reference) (i.e. referenced in Roberts & Simonsen 1963, Biochem. Pharmacol. 12: 113-134, fully incoφorated in the description by reference). Accordingly, PLP has been identified as a critical co-factor in decarboxylation by GAD. Cloning of GAD is disclosed in WO92/05446 and WO92/20811 (both incoφorated by reference). Location of the PLP binding site within the amino acid sequence of hGAD65 was enabled by publication of the cDNA sequence of this enzyme (P.N.A.S. 88:8337, fully incorporated in the description by reference). The site was found because of the homology centred around the amino acid lysine at a/a #396 in hGAD65 - to the sequence: X-His-Lys-X that was previously published as the PLP binding site in crystallised E.coli GAD (Biochemistry 9:226-233; Biochemistry 13:670-676, both of which are fully incoφorated in the description by reference). This region in hGAD65 has the following amino acid sequence: Thr Tφ Asn Pro His Lys* Met Met Gly Val T W N P H K* M M G V #391 #396 #400 * selected herein for mutation to change K to Arg (R) This homology in this region has subsequently been confirmed by Lernmark (unpublished) using computer homology matches to ca. 10 other PLP-binding (non-GAD) proteins. The approach ofthe present invention is a novel GAD without enzyme activity by mutating a single codon in the PLP binding site in the cDNA sequence for hGAD65. This results in the substitution of a single amino acid that is incapable of supporting wild-type enzyme activity. As the lysine at #396 has been identified as critical for enzyme activity (via formation of a Schiff base during GAD-mediated decarboxylation), the present invention is directed to substitute an amino acid incapable of Schiff base formation at position #396 as a subtle means of achieving this effect. In addition, a "conservative amino acid substitution" (i.e. replacement of lysine by an amino acid of comparable size and hydrophobicity) is intended to minimise any structural or conformational changes to the hGAD65 protein, and thereby avoid alterations to either antigenic etitopes or T cell determinants originally present in recombinant human GAD (rhGAD65). Summary of the invention The present invention relates to a modified, non-enzymically active hGAD65 retaining the immunoreactive characteristics of wild type hGAD65, wherein amino acid #396 has been altered an L-amino acid other than lysine. It is preferred to alter amino acid #396 to an amino acid chosen from the group of isoleucine, arginine, glutamine, histidine or glycine. In a particularly preferred embodiment of the present invention amino acid #396 is altered to arginine. Detailed description of the invention As already mentioned, the modified hGAD65 protein having considerably reduced enzymatic activity constitutes an object of the present invention. This altered protein can be used for treating auto-immune diseases, such as IDDM. "Modified hGAD65 protein" as utilized herein refers to human glutamic acid decarboxylase having a molecular weight of 65 kDa wherein amino acid #396 has been altered to an amino acid other than lysine, and whose enzymatic activity has been considerably reduced. In a preferred embodiment, the altered amino acid is chosen from the group of isoleucine, arginine, glutamine, histidine and glycine. Of these, arginine is considered to be most preferred as it is unable to form a Schiff base, but has similar hydrophobicity (index of both is 3.0) and size compared to lysine. The amino acid sequence of this modified hGAD65 protein is disclosed as SEQ. ID. NO. 3 The present invention also relates to nucleic acid sequences encoding a modified hGAD65 protein taken into account the degenerated genetic code. A preferred embodiment is disclosed as SEQ. ID. NO. 2. In an other aspect, the present invention relates to an oligonucleotide that can be used for altering amino acid #396 to an amino acid other than lysine by site-directed mutagenesis of a nucleic acid encoding wild-type hGAD65. A preferred embodiment of such an oligonucleotide is disclosed as SEQ. ID. NO. 1. In another aspect, the present invention relates to vectors and host cells comprising the above mentioned nucleic acids encoding modified hGAD65 protein. The nucleic acids may be readily introduced into a wide variety of host cells. Representative examples of such host cells include plant cells, eukaryotic cells and prokaryotic cells. Within preferred embodiments, the nucleic acid molecules are introduced into cells from an insect or a vertebrate or warm-blooded anomal, such as a human, macaque, dog, cow, horse, pig, sheep, rat hamster, mouse, or a fish, or any hybrid thereof. The nucleic acid molecules (or vectors) may be introduced into host cells by a wide variety of mechanisms, including for example calcium phosphate-mediated transfection (Wigler et al., Cell 14:725, 1978, fully incoφorated in the description by reference), lipofection; gene gun (Corsaro and Pearson, Somatic Cell Gen. 1 :603. 1981; Graham and Van der Eb, Virology 52:456, 1973; both of which are fully incoφorated in the description by reference), electroporation (Neumann et al., EMBO J. 1 :841-845, 1982, fully incoφorated in the description by reference), retroviral, adenoviral protoplast- mediated transfection or DEAE-dextran mediated transfection (Ausubel et al., (eds), Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, NY, USA 1987, fully incorporated in the description by reference) as well as baculovirus transfection, such as the method described in EP 0 327 180 (fully incorporated in the description by reference). As noted above, the present invention also provides a variety of pharmaceutical compositions for treating and/or preventing autoimmune diseases, such as IDDM, comprising pharmaceutically active amount of a modified hGAD65 protein along with a pharmaceutically or physiologically acceptable carrier, excipients or diluents. Generally, such carriers should be non-toxic to recipients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining the therapeutic agent with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrins, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered saline or saline mixed with non-specific serum albumin are exemplary appropriate diluents. In addition, the pharmaceutical compositions of the present invention may be prepared for administration by a variety of routes, including for example orally, sublingually, rectally, intraarticularly, intracranially, intradermally, intramuscularly, intraocularly, intraperitoneally, intravenously or subcutaneously. The compositions can occur as tablets, sublingual tablets, granules, pills, capsules, dragees, solutions, syrups, mixtures, emulsions, suppositorys, aerosols, etc. Furthermore, the above mentioned nucleic acid molecules can be used as pharmaceuticals and directly be injected into a human or animal in need of such treatment by using a gene gun (Corsaro and Pearson, Somatic Cell Gen. 1 :603, 1981; Graham and Van der Eb, Virology 52:456, 1973; both of which are fully incoφorated in the description by reference). The treated human or animal body are then able to synthesize the modified hGAD65 according to the present invention. As already mentioned, GAD is expressed by CNS, but also by islet cells in pancrease even producing insulin. GAD 65 is regarded to be the antigen initiating the immune response leading to diabetes, type 1 (IDDM). A GAD similar antigen has also been identified on Epstein Barr transformed lymphocytes and in coxsackie virus-infected cells. The influence of GAD 65 and the relation between IDDM and the presence of GAD 65 are described in Kaufman et al., Nature 361 :69, 1993; and November 4th, 1993, pp 69- 71, incoφorated by reference. Accordingly the present invention concerns a method to prevent and to treat LDDM by inducing a tolerance to GAD as well as a GAD for such a treatment. The method can be used on all or certain population segments with the object to eliminate or to minimize the IDDM frequency, at least of GAD initiated IDDM. The method can be adapted above all to individuals with a genetic predisposition for IDDM and to individuals with an increased antibody titer against GAD with the object to lead the at least in the last mentioned case already started autoimmune reaction in regress. The method can also be used with patients with a developed LDDM to eliminate the possibility of a renewned autoimmune attack after e.g. a pancreas or an islet cell transplantation. The method relates tro modifying the DNA sequence coding GAD in such a way that the efficiency of the produced peptide in the connection with GABA decreases or vanishes without thereby its diabetes autoimmune antigenic features disappearing. In this way GAD can be used more safely for human beings and thus GAD can be administered in various ways for introducing tolerance. For the participation of GAD as an enzyme during the splitting of Glutamatic Acid into GABA and carbon dioxide the presence of a cofactor PLP (pyridoxal-5'-phosphate) is required. The PLP binding site consists of aminoacid 395-397 of wild type hGAD65. By replacing the aminoacid #396 with another amino acid the binding site for PLP is influenced so that said cofactor PLP is not bound to said binding site on the GAD molecule resulting in that said GAD molecule no longer participates in the GABA synthesis. The modification at said binding site is not influencing the GAD epitope being diabetogenerating. The modified GAD molecule is expressed with a known recombinant technique. The manufacturing of cDNA from mRNA is well known today. The modified hGAD65 protein produced is then used to treat IDDM. This modified hGAD65 so obtained is useful as an immunomodulant therapeutic to prevent certain autoimmune diseases (including insulin-dependent diabetes mellitus) and certain other diseases (including neurological diseases). The provision of this is a novel means to avoid (or minimise) the risk of toxicity (e.g. neurotoxicity) possibly arising from the enzyme activity of a GAD-based immuno-therapeutic. From now on, the invention will be described with reference to the enclosed examples. However, it should be understood that the scope of the present invention is not to be restricted to those examples. Materials and methods 1. DNA oligomer design and synthesis Both oligos (below) represent sequences from the coding strand of both the insert or vector, and are intended to hybridise to the same (ie. non-coding) strand of p65 (Synectics proprietary clone derived from the cDNA sequence for human GAD65 published by Karlsen et al 1991 Proc. Natl. Acad. Sci USA 88:8337-8341 and Bu et al. 1992 Proc. Natl. Acad. Sci USA 89:2115-2119; both of which are fully incorporated in the description by reference). The mutagenic primer (SEQ. ID. NO. 1) was designed according to Stratagene recommendations and contained the CGC codon for Arginine, flanked at either end by 14 nts derived from the corresponding hGAD65 cDNA sequence. Of the 6 alternative codons for Arginine (viz. AGA, AGG, CGA, CGC, CGG, CGU), the codon CGC was selected as this has the greatest usage in animals (Grantham R, Gautier C, Gouy M, Jacobzone M, Mercier R 1981 Nucleic Acid Res 9:43-74: fully incoφorated in the description by reference). Accordingly, the 31-mer mutagenic oligo has sequence: 5'-CGTGGAATCCACACCGCATGATGGGAGTCCC-3' (SEQ.fD.NO 1) -corresponding to nt #1 186 (upstream end) and #1216 (downstream) of p65. This mutagenic primer (coded "SDM-PLP") was synthesised at the Karonlinska Institute facility, and kinased (via T4 polynycleotide kinase, see Current Protocols in Molecular Biology, John Wiley & Sons, Inc., fully incoφorated in the description by reference) prior to use. The Tm of SDM-PLP is estimated as 60° C and was used during mutagenesis. The Sea I to Mlu I selection pπmer was chosen because of the absence of sites in the rhGAD65 insert and the single site in the pGEM4z vector of p65 This kinased pπmer was supplied by Stratagene (catalogue #300331) 2. Site-directed mutagenesis of proprietary hGAD65 clone "p65" The Chameleon double- stranded DNA site-directed mutagenesis kit from Stratagene was used for modification ofthe Synectics Biotechnology rhGAD65 clone (coded "p65"), and followed the manufacturers' instructions m the instruction manual (Catalog #200509, June 13, 1994, fully incoφorated in the descnption by reference) 3. DNA sequencing of candidate clones The required mutation (present in clone #18) was confirmed by DNA sequencing using "Taq DyeDeoxy Terminator Cycle Sequencing" (Applied BioSystems) and "ALF" sequenator at the Karonlinska facility. The sequencing oligo "JR11" (annealing to nts #1353-1369 in the coding strand) was used to confirm sequence at nts "1200-1202. Oligo "JR4" (annealing to the noncoding strand upstream of nts "1200-1202, at nts #1033- 1050) was used to obtain seqence in a downstream direction to the site of the mutation Methods used for these mampulations followed previously-published procedures (e.g Cunent Protocols in Molecular Biology, John Wiley & Sons, Inc; Sambrook, Fπtsch & Maniatis Molecular Clomng: A Laboratory Manual. Cold Spπng Harbor Laboratory Press, 1989; both of which are fully incoφorated in the descnption by reference). 4. Check for comparable immunoreactivity between mutant and wild-type Immunoreactivity of the in vitro transcribed/translated mutant rhGAD65 cDNA (clone #18) was shown to be indistinguishable from the onginal (non-mutant) p65 clone by using IDDM sera in a radioimmunoassay specific for GAD65 autoanti bodies (Falorni et al. 1993 Diabetologia 36 (suppl. 1) A45; Falorni et al. 1994 Autoimmunity 19 113-125, both of which are fully incorporated in the descnption by reference) This analysis compared immunoreactivity of the mutant and wild-type clones by comparing radioactivity precipitated by ca 20GAD65-positive IDDM sera on incubation with 35s-labelled rhGAD65 protein synthesised in vitro from either the wild-type or mutant rhGAD65 cDNA clones. Example 1 : Site-directed mutagenesis of wild-type hGAD65 An oligonucleotide having the sequence: 5'-CGTGGAATCCACACCGCATGATGGGAGTCCC-3 1 (SEQ.ID.NO 1) was synthesized, phosphorylated and used to mutate a cDNA having the sequence of fig. 2 in Karlsen et al., P.N.A.S. 88:8337, 1991 (incorporated into the description by reference) according the instructions in the above mentioned Chamelon™ kit. Competent Escherichia coli F l 1 rec A cells were transformed with p65 mutant plasmids. Positive clones were screened by DNA sequencing using the Taq DyeDeoxy™ Terminator Cycle Sequencing Kit from Applied Biosystems. A clone containing the desired mutatant were found. Example 2: In vitro translation of 35 S-mutant hGAD65 Recombinant modified human GAD65 was produced by in vitro transcription/translation of the cDNA inserted into the pGEM4z vector. The translation reaction was carried out using SP6 RNA polymerase and rabbit reticulocyte lysate. The materials used in the experiment were part of the TNT coupled transcription/translation system from Promega. The following reaction mixture was prepared: Plasmid DNA encoding modified hGAD65 (2mg/ml) 1 ul RNAsin (Promega) 1 μl TNT buffer 2 μl Amino acid mixture (without methionine)(Promega) 1 μl 35 S-methionine (NEN-Dupont) 4 μl SP6 RNA polymerase (Promega) 1 μl Rabbit Reticulocyte lysate (Promega) 25 μl Water up to 50 μl The reactions were incubated for 90 minutes at 30°C. At the end of the incubation time, 2 ml from the reaction tube was incubated for 10 minutes at 37°C with IM NaOH/2% H 2 0 2 and 30 minutes on ice with 0.9 ml 25% trichloroacetic acid (TCA) in order to precipitate proteins that may have been formed. The TCA precipitate was collected on a GF-A Whatman glass fibre filter and its radioactivity was evaluated in a liquid scintillation analyser. It was shown that the precipitate was radioactive and hence, modified hGAD65 was formed. Example 3: Immunoprecipitation of 35S-modified hGAD65 with IDDM sera In vitro translated modified hGAD65 from example 2 was immunoprecipitated with EDDM sera to test the immunoreactivity. For each serum sample 15000 cpm TCA- precipitable GAD65 was precipitated with 2 μl of human serum from healthy or diabetic individuals (final serum dilution 1 :50). After overnight immunoprecipitation in cold room, antibody bound 35 S-modified hGAD65 was separated from free 3S S-modified hGAD65 by protein A Sepharose using a Multiscreen Assay Millipore system. Iinmunoprecipitated radioactivity was evaluated in a liquid scintillation analyzer. Immunoprecipitation of 35 S-modified hGAD65 for diabetic sera was significantly higher than that obtained with sera from healthy persons. The used diabetic sera were previously found positive for antibodies against wild type hGAD65. Hence, it was concluded that modified hGAD65 has an immunoreactivity similar to that of wild type hGAD65. SEQUENCE LISTING ( 1 ) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Synetics Medical AB (B) STREET: Renstiernas gata 12 (C) CITY: Stockholm (E) COUNTRY: Sweden (F) POSTAL CODE (ZIP): 116 28 (ii) TITLE OF INVENTION: A modified glutamic acid decarboxylase. (iii) NUMBER OF SEQUENCES: 3 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO) (v) CURRENT APPLICATION DATA: APPLICAΗON NUMBER: SE 9503379-1 (2) INFORMATION FOR SEQ ID NO: 1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1 : CGTGGAATCC ACACCGCATG ATGGGAGTCC C 31 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1761 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (xi) SEQUENCE DESCRIPTION: SEQ LD NO: 2: ATGGCATCTC CGGGCTCTGG CTTTTGGTCT TTCGGGTCGG AAGATGGCTC TGGGGATTCC 60 GAGAATCCCG GC AC AGCGCG AGCCTGGTGC C AAGTGGCTC AGAAGTTC AC GGGCGGC ATC 120 GGAAAC AAAC TGTGCGCCCT GCTCTACGGA GACGCCGAGA AGCCGGCGGA GAGCGGCGGG 180 AGCCAACCCC CGCGGGCCGC CGCCCGGAAG GCCGCCTGCG CCTGCGACCA GAAGCCCTGC 240 AGCTGCTCCA AAGTGGATGT CAACTACGCG TTTCTCCATG CAACAGACCT GCTGCCGGCG 300 TGTGATGGAG AAAGGCCC AC TTTGGCGTTT CTGC AAGATG TTATGAAC AT TTTACTTC AG 360 TATGTGGTGA AAAGTTTCGA TAGATCAACC AAAGTGATTG ATTTCCATTA TCCTAATGAG 420 CTTCTCCAAG AATATAATTG GGAATTGGC A GACC AACC AC • AAAATTTGGA GGAAATTTTG 480 ATGCATTGCC AAACAACTCT AAAATATGCA ATTAAAACAG GGCATCCTAG ATACTTCAAT 540 C AACTTTCTA CTGGTTTGGA TATGGTTGGA TTAGCAGCAG ACTGGCTGAC ATC AAC AGCA 600 AATACTAACA TG-TCACCTA TGAAATTGCT CCAGTATΓΓG TGCTTTTGGA ATATGTCACA 660 CTAAAGAAAA TGAGAGAAAT C ATTGGCTGG CCAGGGGGCT CTGGCCATGG GATATTTTCT 720 CCCGGTGGCG CCATATCTAA CATGTATGCC ATGATGATCG CAGCGTTTAA GATGTTCCCA 780 GAAGTC AAGG AGAAAGGAAT GGCTGCTCTT CCC AGGCTC A TTGCCTTC AC GTCTGAAC AT 840 AGTCATTTTT CTCTC AAGAA GGGAGCTGCA GCCGTAGGGA TTGGAACAGA CAGCGTGATT 900 CTGATTAAAT GTGATGAGAG AGGGAAAATG ATTCCATCTG ATCTTGAAAG AAGGATTCTT 960 GAAGCC AAAC AGAAAGGGTT TGTTCCTTTC CTCGTGAGTG CC AC AGCTGG AACC ACCGTG 1020 TACGGAGCAT TTGACCCCCT CTTAGCTGTC GCTGACATTT GC AAAAAGTA TAAGATCTGG 1080 ATGCATGTGG ATGCAGCTTG GGGTGGGGGA TTACTGATGT CCCGAAAACA CAAGTGGAAA 1140 CTGAGTGGCG TGGAGAGGGC CAACTCTGTG ACGTGGAATC CACACCGCAT GATGGGAGTC 1200 CCTTTGCAGT GCTCTGCTCT CCTGGTTAGA GAAGAGGGAT TGATGCAGAA TTGCAACC AA 1260 ATGCATGCCT CCTACCTCTT TCAGCAAGAT AAACATTATG ACCTGTCCTA TGACACTGGA 1320 GACAAGGCCT TAC AGTGCGG ACGCCACGTT GATGTTTTTA AACTATGGCT GATGTGGAGG 1380 GC AAAGGGGA CTACCGGGTT TGAAGCGC AT GTTGATAAAT GTTTGGAGTT GGC AGAGTAT 1440 TTATAC AAC A TC ATAAAAAA CCGAGAAGGA TATGAGATGG TGTTTGATGG GAAGCCTC AG 1500 CACACAAATG TCTGCTTCTG GTACATTCCT CCAAGCTTGC GTACTCTGGA AGACAATGAA 1560 GAGAGAATGA GTCGCCTCTC GAAGGTGGCT CC AGTGATTA AAGCC AGAAT GATGGAGTAT 1620 GGAACC AC AA TGGTC AGCTA CC AACCCTTG GGAGAC AAGG TC AATTTCTT CCGC ATGGTC 1680 ATCTC AAACC C AGCGGC AAC TC ACC AAGAC ATTGACTTCC TGATTGAAGA AATAGAACGC 1740 CTTGGAC AAG ATTTATAATA A 1761 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 585 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (xi) SEQUENCE DESCRIPTION: SEQ LD NO: 3: Met Ala Ser Pro Gly Ser Gly Phe Tφ Ser Phe Gly Ser Glu Asp Gly 1 5 10 15 Ser Gly Asp Ser Glu Asn Pro Gly Thr Ala Arg Ala Tφ Cys Gin Val 20 25 30 Ala Gin Lys Phe Thr Gly Gly Lie Gly Asn Lys Leu Cys Ala Leu Leu 35 40 45 Tyr Gly Asp Ala Glu Lys Pro Ala Glu Ser Gly Gly Ser Gin Pro Pro 50 55 60 Arg Ala Ala Ala Arg Lys Ala Ala Cys Ala Cys Asp Gin Lys Pro Cys 65 70 75 80 Ser Cys Ser Lys Val Asp Val Asn Tyr Ala Phe Leu His Ala Thr Asp 85 90 95 Leu Leu Pro Ala Cys Asp Gly Glu Arg Pro Thr Leu Ala Phe Leu Gin 100 105 110 Asp Val Met Asn Lie Leu Leu Gin Tyr Val Val Lys Ser Phe Asp Arg 115 120 125 Ser Thr Lys Val De Asp Phe His Tyr Pro Asn Glu Leu Leu Gin Glu 130 135 140 Tyr Asn Tφ Glu Leu Ala Asp Gin Pro Gin Asn Leu Glu Glu De Leu 145 150 155 160 Met His Cys Gin Thr Thr Leu Lys Tyr Ala De Lys Thr Gly His Pro 165 170 175 Arg Tyr Phe Asn Gin Leu Ser Thr Gly Leu Asp Met Val Gly Leu Ala 180 185 190 Ala Asp Tφ Leu Thr Ser Thr Ala Asn Thr Asn Met Phe Thr Tyr Glu 195 200 205 lie Ala Pro Val Phe Val Leu Leu Glu Tyr Val Thr Leu Lys Lys Met 210 215 220 Arg Glu lie De Gly Tφ Pro Gly Gly Ser Gly Asp Gly He Phe Ser 225 230 235 240 Pro Gly Gly Ala He Ser Asn Met Tyr Ala Met Met He Ala Arg Phe 245 250 255 Lys Met Phe Pro Glu Val Lys Glu Lys Gly Met Ala Ala Leu Pro Arg 260 265 270 Leu He Ala Phe Thr Ser Glu His Ser His Phe Ser Leu Lys Lys Gly 275 280 285 Ala Ala Ala Leu Gly De Gly Thr Asp Ser Val He Leu De Lys Cys 290 295 300 Asp Glu Arg Gly Lys Met De Pro Ser Asp Leu Glu Arg Arg De Leu 305 310 315 320 Glu Ala Lys Gin Lys Gly Phe Val Pro Phe Leu Val Ser Ala Thr Ala 325 330 335 Gly Thr Thr Val Tyr Gly Ala Phe Asp Pro Leu Leu Ala Val Ala Asp 340 345 350 De Cys Lys Lys Tyr Lys Ue Tφ Met His Val Asp Ala Ala Tφ Gly 355 360 365 Gly Gly Leu Leu Met Ser Arg Lys His Lys Tφ Lys Leu Ser Gly Val 370 375 380 Glu Arg Ala Asn Ser Val Thr Tφ Asn Pro His Arg Met Met Gly Val 385 390 395 400 Pro Leu Gin Cys Ser Ala Leu Leu Val Arg Glu Glu Gly Leu Met Gin 405 410 415 Asn Cys Asn Gin Met His Ala Ser Tyr Leu Phe Gin Gin Asp Lys His 420 425 430 Tyr Asp Leu Ser Tyr Asp Thr Gly Asp Lys Ala Leu Gin Cys Gly Arg 435 440 445 His Val Asp Val Phe Lys Leu Tφ Leu Met Tφ Arg Ala Lys Gly Thr 450 455 460 Thr Gly Phe Glu Ala His Val Asp Lys Cys Leu Glu Leu Ala Glu Tyr 465 470 475 480 Leu Tyr Asn De De Lys Asn Arg Glu Gly Tyr Glu Met Val Phe Asp 485 490 495 Gly Lys Pro Gin His Thr Asn Val Cys Phe Tφ Tyr De Pro Pro Ser 500 505 510 Leu Arg Thr Leu Glu Asp Asn Glu Glu Arg Met Ser Arg Leu Ser Lys 515 520 525 Val Ala Pro Val De Lys Ala Arg Met Met Glu Tyr Gly Thr Thr Met 530 535 540 Val Ser Tyr Gin Pro Leu Gly Asp Lys Val Asn Phe Phe Arg Met Val 545 550 555 560 De Ser Asn Pro Ala Ala Thr His Gin Asp De Asp Phe Leu De Glu 565 570 575 Glu De Glu Arg Leu Gly Gin Asp Leu 580 585

Claims: Claims 1. A modified glutamic acid decarboxylase having amino acid sequence: Met Ala Ser Pro Gly Ser Gly Phe Tφ Ser Phe Gly Ser Glu Asp Gly 1 10 15 Ser Gly Asp Ser Glu Asn Pro Gly Thr Ala Arg Ala Tφ Cys Gin Val 20 25 30 Ala Gin Lys Phe Thr Gly Gly De Gly Asn Lys Leu Cys Ala Leu Leu 35 40 45 Tyr Gly Asp Ala Glu Lys Pro Ala Glu Ser Gly Gly Ser Gin Pro Pro 50 55 60 Arg Ala Ala Ala Arg Lys Ala Ala Cys Ala Cys Asp Gin Lys Pro Cys 65 70 75 80 Ser Cys Ser Lys Val Asp Val Asn Tyr Ala Phe Leu His Ala Thr Asp 85 90 95 Leu Leu Pro Ala Cys Asp Gly Glu Arg Pro Thr Leu Ala Phe Leu Gin 100 105 110 Asp Val Met Asn De Leu Leu Gin Tyr Val Val Lys Ser Phe Asp Arg 115 120 125 Ser Thr Lys Val De Asp Phe His Tyr Pro Asn Glu Leu Leu Gin Glu 130 135 140 Tyr Asn Tφ Glu Leu Ala Asp Gin Pro Gin Asn Leu Glu Glu De Leu 145 150 155 160 Met His Cys Gin Thr Thr Leu Lys Tyr Ala De Lys Thr Gly His Pro 165 170 175 Arg Tyr Phe Asn Gin Leu Ser Thr Gly Leu Asp Met Val Gly Leu Ala 180 185 190 Ala Asp Tφ Leu Thr Ser Thr Ala Asn Thr Asn Met Phe Thr Tyr Glu 195 200 205 De Ala Pro Val Phe Val Leu Leu Glu Tyr Val Thr Leu Lys Lys Met 210 215 220 Arg Glu De De Gly Tφ Pro Gly Gly Ser Gly Asp Gly De Phe Ser 225 230 235 240 Pro Gly Gly Ala De Ser Asn Met Tyr Ala Met Met De Ala Arg Phe 245 250 255 Lys Met Phe Pro Glu Val Lys Glu Lys Gly Met Ala Ala Leu Pro Arg 260 265 270 Leu De Ala Phe Thr Ser Glu His Ser His Phe Ser Leu Lys Lys Gly 275 280 285 Ala Ala Ala Leu Gly De Gly Thr Asp Ser Val De Leu De Lys Cys 290 295 300 Asp Glu Arg Gly Lys Met De Pro Ser Asp Leu Glu Arg Arg De Leu 305 310 315 320 Glu Ala Lys Gin Lys Gly Phe Val Pro Phe Leu Val Ser Ala Thr Ala 325 330 335 Gly Thr Thr Val Tyr Gly Ala Phe Asp Pro Leu Leu Ala Val Ala Asp 340 345 350 De Cys Lys Lys Tyr Lys De Tφ Met His Val Asp Ala Ala Tφ Gly 355 360 365 Gly Gly Leu Leu Met Ser Arg Lys His Lys Tφ Lys Leu Ser Gly Val 370 375 380 Glu Arg Ala Asn Ser Val Thr Tφ Asn Pro His Xxx Met Met Gly Val 385 390 395 400 Pro Leu Gin Cys Ser Ala Leu Leu Val Arg Glu Glu Gly Leu Met Gin 405 410 415 Asn Cys Asn Gin Met His Ala Ser Tyr Leu Phe Gin Gin Asp Lys His 420 425 430 Tyr Asp Leu Ser Tyr Asp Thr Gly Asp Lys Ala Leu Gin Cys Gly Arg 435 440 445 His Val Asp Val Phe Lys Leu Tφ Leu Met Tφ Arg Ala Lys Gly Thr 450 455 460 Thr Gly Phe Glu Ala His Val Asp Lys Cys Leu Glu Leu Ala Glu Tyr 465 470 475 480 Leu Tyr Asn De De Lys Asn Arg Glu Gly Tyr Glu Met Val Phe Asp 485 490 495 Gly Lys Pro Gin His Thr Asn Val Cys Phe Tφ Tyr De Pro Pro Ser 500 505 510 Leu Arg Thr Leu Glu Asp Asn Glu Glu Arg Met Ser Arg Leu Ser Lys 515 520 525 Val Ala Pro Val De Lys Ala Arg Met Met Glu Tyr Gly Thr Thr Met 530 535 540 Val Ser Tyr Gin Pro Leu Gly Asp Lys Val Asn Phe Phe Arg Met Val 545 550 555 560 De Ser Asn Pro Ala Ala Thr His Gin Asp De Asp Phe Leu De Glu 565 570 575 Glu De Glu Arg Leu Gly Gin Asp Leu 580 585 wherein Xxx represents a L amino acid other than Lysine. 2. A modified glutamic acid decarboxylase according to claim 1, characterized in that Xxx is chosen from the group of isoleucine, arginine, glutamine, histidine or glycine. 3. A modified glutamic acid decarboxylase according to claim 2, characterized in that Xxx is arginine. 4. A nucleotide sequence encoding a glutamic acid decarboxylase according to any of claims 1 - 3. 5. A nucleotide sequence according to claim 4 which is the one disclosed herein as SEQ. LD. NO. 2. 6. A pharmaceutical composition comprising a therapeutically effective amount of a modified glutamic acid decarboxylase according to any of claims 1-3 together with a pharmaceutically acceptable carrier, excipient and/or diluent. 7. Use of a modified glutamic acid decarboxylase according to any of claims 1 -3 for preparing a pharmaceutical composition for treating and/or preventing autoimmune disorders, such as LDDM. 8. A method for treating and/or preventing autoimmune disorders, such as IDDM, where a modified glutamic acid decarboxylase according to any of claims 1-3 is administrated to a human and/or animal. 9. A nucleotide sequence according to any of claims 4-5 for medical use. 10. A nucleotide sequence according to any of claims 4-5 for genetic vaccination. 11. An oligonucleotide for modifying glutamic acid decarboxylase, characterized in that it encodes the aminoacid sequence Thr Tφ Asn Pro His Xxx Met Met Gly Val wherein Xxx denotes an aminoacid other than Lys. 12. An oligonucleotide according to claim 10 having the sequence disclosed as SEQ.LD.No. l. 13. A vector containing the nucleic acid sequence according to any of claims 4-5. 14. A host cell containing a vector according to claim 12. 15. A procedure for producing a modified glutamic acid decarboxylase according to any of claims 1-3 characterized in cultivating a host cell according to claim 13 under suitable conditions.

Inventors: ESSEN-MOELLER ANDERS, FALORNI ALBERTO, LERNMARK AAKE, ROBERTSON JOHN, ESSEN-MOELLER, ANDERS, FALORNI, ALBERTO, LERNMARK, AAKE, ROBERTSON, JOHN
Applicants: ESSEN MOELLER ANDERS, FALORNI ALBERTO, LERNMARK AAKE, ROBERTSON JOHN, SYNECTICS BIOTECHNOLOGY AB, ESSEN-MOELLER, ANDERS, FALORNI, ALBERTO, LERNMARK, AAKE, ROBERTSON, JOHN
Application year: 1996
Main classification: C12N9
IPC codes: A61K38, C12N9, C12N15